306 related articles for article (PubMed ID: 29276060)
21. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
[TBL] [Abstract][Full Text] [Related]
22.
Smile TD; Tom MC; Halima A; Ciezki JP; Reddy CA; Stephans KL; Mian OY; Zhang RX; Klein EA; Campbell S; Ulchaker J; Angermeier K K; Tendulkar RD
Brachytherapy; 2022; 21(1):85-93. PubMed ID: 34656435
[TBL] [Abstract][Full Text] [Related]
23. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.
Kishan AU; Karnes RJ; Romero T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Braccioforte M; Huland H; Tran PT; Martin S; Martínez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Chang AJ; Pisansky TM; Choo R; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; D'Amico AV; Rettig MB; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D
JAMA Netw Open; 2021 Jul; 4(7):e2115312. PubMed ID: 34196715
[TBL] [Abstract][Full Text] [Related]
25. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.
Rosenberg JE; Chen MH; Nguyen PL; Braccioforte MH; Moran BJ; D'Amico AV
Clin Genitourin Cancer; 2012 Mar; 10(1):21-5. PubMed ID: 22130293
[TBL] [Abstract][Full Text] [Related]
26. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.
Jackson WC; Hartman HE; Dess RT; Birer SR; Soni PD; Hearn JWD; Reichert ZR; Kishan AU; Mahal BA; Zumsteg ZS; Efstathiou JA; Kaffenberger S; Morgan TM; Mehra R; Showalter TN; Krauss DA; Nguyen PL; Schipper MJ; Feng FY; Sandler HM; Hoskin PJ; Roach M; Spratt DE
J Clin Oncol; 2020 Sep; 38(26):3024-3031. PubMed ID: 32396488
[TBL] [Abstract][Full Text] [Related]
27. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
28. Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis.
Mendez LC; Martell K; Warner A; Tseng CL; Chung H; Loblaw A; Rodrigues GB; Morton G
Radiother Oncol; 2020 Sep; 150():195-200. PubMed ID: 32619455
[TBL] [Abstract][Full Text] [Related]
29. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
30. Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy.
Schiffmann J; Lesmana H; Tennstedt P; Beyer B; Boehm K; Platz V; Tilki D; Salomon G; Petersen C; Krüll A; Graefen M; Schwarz R
Strahlenther Onkol; 2015 Apr; 191(4):330-7. PubMed ID: 25471276
[TBL] [Abstract][Full Text] [Related]
31. Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer.
Sebastian NT; McElroy JP; Martin DD; Sundi D; Diaz DA
Urol Oncol; 2019 Nov; 37(11):813.e11-813.e19. PubMed ID: 31109836
[TBL] [Abstract][Full Text] [Related]
32. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.
Tilki D; Chen MH; Wu J; Huland H; Graefen M; Braccioforte M; Moran BJ; D'Amico AV
JAMA Oncol; 2019 Feb; 5(2):213-220. PubMed ID: 30452521
[TBL] [Abstract][Full Text] [Related]
33. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
34. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
Keyes M; Merrick G; Frank SJ; Grimm P; Zelefsky MJ
Brachytherapy; 2017; 16(2):245-265. PubMed ID: 28110898
[TBL] [Abstract][Full Text] [Related]
35. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
[TBL] [Abstract][Full Text] [Related]
36. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA
Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405
[TBL] [Abstract][Full Text] [Related]
37. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
Matzkin H; Chen J; Agai R; Ziv-Baran T; Mabjeesh NJ
PLoS One; 2019; 14(4):e0215582. PubMed ID: 31002732
[TBL] [Abstract][Full Text] [Related]
38. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer.
Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N
Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436
[TBL] [Abstract][Full Text] [Related]
39. Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer?
Tabata R; Kimura T; Kuruma H; Sasaki H; Kido M; Miki K; Takahashi H; Aoki M; Egawa S
Cancer Med; 2016 Sep; 5(9):2314-22. PubMed ID: 27456710
[TBL] [Abstract][Full Text] [Related]
40. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]